Going green Next Generation Pharmaceutical (Europe)              Collaboration and innovation Next Generation Pharmaceutical (Europe)              Pushing the frontiers of disease prevention Next Generation Pharmaceutical (Europe)              The power of perception Next Generation Pharmaceutical (Europe)              Supply chain optimisation Next Generation Pharmaceutical (Europe)              Translational medicine paradigm: hip or hype? Next Generation Pharmaceutical (US)              The evolution of drug safety Next Generation Pharmaceutical (US)              Investigating cell death resistance in tumor cells Next Generation Pharmaceutical (US)              A culture of engagement and inclusion Next Generation Pharmaceutical (US)              Leading Lilly forward Next Generation Pharmaceutical (US)             

Contributors

John Lechleiter
John Lechleiter
COO, Eli Lilly
Leading Lilly forward

Ken Murtha
Ken Murtha
Regional VP Supply for the Americas, AstraZeneca
The importance of operations

Jill Robinson
Jill Robinson
VP of Global Safety Surveillance, Wyeth Research
The new risk management paradigm

Mary Ellen Turner
Mary Ellen Turner
VP Risk Management, Wyeth Research
The new risk management paradigm

Dr. Andreas Busch
Dr. Andreas Busch
Head of Global Drug Discovery, Bayer Schering Pharma
Big in Germany

Tracy Lefteroff
Tracy Lefteroff
Price Waterhouse Coopers
Looking to the future

Outsourcing

The CRO market size is estimated at $10 Billion and growing. CROs provide product development services to the pharmaceutical and biotechnology industries, allowing their clients to manage product-development efforts more efficiently and cost-effectively. There is a demand for CRO professionals to bring their scientific, regulatory and information management expertise to bear for the completion of timely, accurate, cost-effective trials. By outsourcing, sponsors gain the benefits of CRO experience, even while controlling costs and reducing the research and development timeline.

The growing trend in outsourcing includes the purchasing of products as well as services and ranges from manufacturing through to IT and logistics. Inevitable signs of globalization simply cannot be overlooked in the face of competition:oof-shore and near shore partners allow executives to align their enterprise and culture with consumer demand in the global market.

Outsourcing their non-core processes allows pharmaceutical companies to concentrate on their core processes, which strengthens their operations, increasing market presence and shareholders’ value.

R&D capabilities: A value-added feature in a central laboratory
Choosing a provider that combines pure research and development expertise with central laboratory experience is a definite benefit when considering the long-term optimization of your product development
More >>

The right direction in outsourcing
NGP spoke to Dr Andrew Parkinson Founder, President and CEO of XenoTech
More >>

Leading lights in the fight against cancer
On December 29, 2004, the US Food and Drug Administration approved Clofarabine for use in children with acute lymphoblastic leukemia, making it the first new pediatric anti-cancer drug available in 10 years.
More >>

Strategic outsourcing: the viable option
This article looks at two very different approaches to outsourcing.
More >>

Shaping third party production
Just as in the automobile, electronics and aerospace industries, third party or sub-contracted manufacturing has become an essential strategy for pharmaceutical laboratories.
More >>

A new approach to outsourced pharmaceutical manufacturing
Pharmaceutical companies face a myriad of challenges day in and day out.
More >>

The Publication COVER: Next Generation Pharmaceutical 12

See More >>

Sponsors

Vendor Perspectives

Article
The iuvo Microconduit Array (MCA)
BellBrook Labs
More >>

Article
The Top 3 Grid Application Areas for Pharma R&D: Drug Discovery, Clinical Analysis and Data Management
Univa UD
More >>

Article
4plex, real-time one-step RT-PCR without optimization
QIAGEN
More >>

Article
View from 37,000 feet – weathering change in the Pharmaceutical Industry
Triligent International
More >>

Article
Moving beyond rote case reporting: demonstrating a believable commitment to patient safety
ArisGlobal LLC
More >>

Article
Coping successfully with changing regulations in Experimental Clinical Pharmacology (Phase I)
Simbec Research Ltd
More >>

The Leader